Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Piper Sandler

Piper Sandler began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note issued on Friday, MarketBeat reports. The firm set an “overweight” rating and a $48.00 price target on the stock.

Other analysts also recently issued research reports about the stock. Wedbush began coverage on shares of Avalo Therapeutics in a report on Friday, February 21st. They set an “outperform” rating and a $18.00 price objective for the company. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $35.33.

Avalo Therapeutics Stock Up 10.8 %

Avalo Therapeutics stock opened at $7.31 on Friday. The firm’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $9.27. Avalo Therapeutics has a 1-year low of $4.28 and a 1-year high of $34.46.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new position in Avalo Therapeutics during the 3rd quarter valued at $9,186,000. Ikarian Capital LLC increased its position in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after purchasing an additional 915,629 shares during the period. Affinity Asset Advisors LLC increased its position in Avalo Therapeutics by 1,123.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after purchasing an additional 505,765 shares during the period. Velan Capital Investment Management LP purchased a new position in Avalo Therapeutics during the 4th quarter valued at $817,000. Finally, Geode Capital Management LLC increased its position in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after purchasing an additional 94,742 shares during the period. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.